Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Garetosmab in Fibrodysplasia Ossificans Progressiva
2022-000880-40Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in fibrodysplasia ossificans progressiva (FOP) comparing High-dose garetosmab with Placebo (2 arms). Primary endpoint: Number of new heterotopic ossification lesions. Started Jun 2022; status: active.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2022-000880-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000880-40.